<DOC>
	<DOCNO>NCT01702493</DOCNO>
	<brief_summary>This open-label , randomize , control , single center study assess safety , variability exposure , relative bioavailability new oral formulation SRT2104 . This two part study part consist screen ( within 21 day first schedule dose SRT2104 ) , treatment period follow-up visit ( approximately 6 day last dose ) . Part 1 : Subjects receive four fomulations SRT2104 order dos randomize . Each subject receive one formulation 500 milligram ( mg ) dose ( form two 250 mg capsule tablet ) session give fasted state . Each dose separate least 6 day . Pharmacokinetic ( PK ) sample do pre post schedule dosing session . After 4 dosing session , safety PK data review determine , , formulation ( ) carry forward Part 2 . The total duration approximately 7 week . Part 2 : Is divide Part 2A , 2B 2C study optional . After completion Part 1 , sponsor decide whether proceed Part 2 , whether select formulation ( ) administer fed fast state Parts 2B 2C . For sub part Part 2 pre post-dose PK sample obtain . Part 2A : A single-dose select formulation ( ) Part 1 administered standard meal assess effect food bioavailability SRT2104 500 mg dose . The total duration approximately 4 week . Part 2B : A single alternative dose ( 500 mg , exceed 2000 mg ) select formulation ( ) Part 1 administered ass safety PK profile dose level . The total duration approximately 4 week . Part 2C : The select formulation ( ) Part 1 administer 500 mg dose daily 7 consecutive day , assess safety tolerability characterize PK profile repeat dose . The total duration approximately 5 week .</brief_summary>
	<brief_title>A Study Assess Relative Bioavailability New Oral Formulations SRT2104 Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Healthy determine responsible experienced physician . Males 18 65 year age inclusive , time signing informed consent . Body weight &gt; =50 kilogram ( kg ) ( 110 lb ) body mass index ( BMI ) &gt; =18 . Capable give write informed consent , include compliance requirement restriction list consent form . Past present disease judge investigator potential interfere study procedure compromise subject 's safety . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) , aspartate aminotranferase ( AST ) , alanine aminotranferase ( ALT ) , alkaline phosphatase bilirubin &gt; 1.5 x upper limit normal ( ULN ) . Abnormalities Screening Day 1 : electrocardiogram ( ECG ) , opinion investigator , compromise subject safety study QT correct use Fridericia 's formula ( QTcF ) &gt; 450 millisecond ( msec ) . A history Hepatitis B , Hepatitis C human immunodeficiency virus ( HIV ) , positive serology Screening . History regular alcohol consumption within 6 month Screening ( Screening visit ) positive prestudy drug/alcohol screen . Participation clinical trial treatment investigational product within 3 month prior Screening visit . Use prescription nonprescription drug , include vitamin , herbal dietary supplement . History sensitivity study medication , component thereof history drug allergy contraindicate participation . History sensitivity heparin heparininduced thrombocytopenia . Where participation study would result inability donate blood blood product excess 500 milliliter ( mL ) within 56 day period . Urinary cotinine level indicative smoke history regular use tobacco nicotinecontaining product within 6 month prior screen . Consumption red wine , seville orange , grapefruit grapefruit juice [ and/or pummelo , exotic citrus fruit , grapefruit hybrid fruit juice ] 7 day prior first dose study medication .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>SRT2104</keyword>
	<keyword>Modified Release</keyword>
	<keyword>Bioavailability</keyword>
	<keyword>Crossover</keyword>
</DOC>